Thyroid carcinoma in dogs: treatment, prognosis and clinical trials

Dogs · USA & Canada

Understanding thyroid carcinoma

Thyroid carcinoma usually appears as a mass in the neck. In dogs, a small mobile mass that can be removed is a very different problem from a fixed tumor that wraps around major vessels or has already spread. Tumor mobility, vascular invasion and metastatic stage are central to treatment planning.

What does the prognosis look like?

Many dogs with a localized, movable thyroid tumor can do well for years. A large thyroid-surgery study found a typical survival time of about 26 months, and selected surgically treated dogs have lived beyond three years. A fixed tumor involving major vessels or cancer that has spread is a different situation, so resectability and staging must be known before applying those figures.

What matters next

Find out whether the thyroid mass moves freely or is fixed to surrounding tissues and whether major vessels or both thyroid lobes are involved. That often determines whether surgery is straightforward, whether more imaging is needed and whether radiation, radioactive iodine or systemic treatment should be discussed instead.

Where are you now?

The thyroid mass is mobile and appears resectable

A freely movable thyroid mass can be a good surgical problem in selected dogs. Confirm local anatomy and metastatic stage before assuming that a fixed or invasive-tumor treatment pathway is needed.

The mass is fixed or invasive

Fixed tumors can involve major vessels and surrounding structures. Radiation, radioactive iodine in selected tumors, or systemic treatment may be more realistic than attempting a high-morbidity surgery.

Surgery has already been done

Review margins, vascular invasion, histologic findings, and staging. A removed thyroid carcinoma does not automatically need more treatment; the next step depends on residual disease and metastatic risk.

Metastatic disease is present

Ask whether the tumor is iodine-avid and whether local neck control is still needed. The best systemic option depends on where disease has spread and whether it is progressing.

If you are waiting for oncology

Clarify whether the thyroid mass is mobile or fixed and whether major vessels or surrounding structures are involved. That distinction often matters more than simply knowing that the mass is thyroid in origin.

Questions to ask your oncologist

Is the mass mobile and surgically removable, or fixed/invasive?
Is there vascular invasion or metastatic disease?
Would radioactive iodine, radiation or systemic treatment be preferable to surgery in this anatomy?

How the diagnosis may appear in the record

The record should distinguish a mobile, discrete thyroid tumor from fixed or invasive disease and note whether one or both lobes and major vessels are involved. Pathology may report vascular or capsular invasion and margins. Functional status and iodine avidity are separate questions that can affect selected treatments.

Changes to watch for at home

Report changes in the neck mass, coughing, gagging, noisy breathing, swallowing difficulty, voice change, weakness, or reduced exercise tolerance. Breathing distress or sudden neck swelling is urgent. Hormone-producing tumors may also cause changes in heart rate, thirst, appetite, or weight.

How it is usually treated

Surgery is preferred for a mobile, resectable thyroid tumor. Radiation is useful for invasive, fixed, incompletely removed or non-surgical tumors. Radioactive iodine can be appropriate for selected iodine-avid cancers, while systemic or targeted treatment may be considered for progressive or metastatic disease.

What can affect treatment choices

A mobile removable mass is very different from a fixed invasive one. Vessel involvement, one versus both thyroid lobes, iodine avidity and metastasis determine whether surgery, radiation, radioiodine or systemic treatment is favored.

Tests that may matter

Neck imaging helps show whether the mass is mobile, invasive or involving major vessels. Thyroid hormone testing and chest staging may be useful, while scintigraphy or iodine-uptake assessment matters mainly when radioactive iodine is being considered.

Treatment options available now

4 options currently in our catalog.

Check eligibility

Evaluation of TLR agonist Z-007 in dogs with cancer

Cummings School of Veterinary Medicine, Tufts University · USA

Location

Henry and Lois Foster Hospital for Small Animals, 200 Westboro Rd, North Grafton, MA 01536

Study details

Recruiting

What is being offered: Dog study of IV or intratumoral Z-007 for solid tumors including carcinomas, sarcomas and melanoma. Public criteria include a generally 2–7 cm repeat-biopsy-accessible tumor plus medical/laboratory requirements; no prior immunotherapy or autoimmune disease. Investigator prescreening required.

Who may qualify: Confirmed cancer diagnosis required; Min weight kg: 7; Measurable

May not qualify if: Prior immunotherapy

Costs / coverage: 🟡 Partially funded. Z-007 treatment through Day 63 and treatment of Z-007/biopsy-related side effects are covered; other owner costs should be confirmed with Tufts.

Contact: clinicaltrials@tufts.edu

Official study / enrollment information →

Histotripsy for canine thyroid tumors

Virginia-Maryland College of Veterinary Medicine / Virginia Tech · USA

Location

Veterinary Teaching Hospital, 245 Duck Pond Dr, Blacksburg, VA 24061

Study details

Recruiting — listed on Virginia Tech current studies page

What is being offered: Dogs must have a thyroid tumor whose owners have elected surgical removal, and must be stable enough for general anesthesia. Non-resectable tumors and other life-threatening disease are excluded. Eligible dogs receive one histotripsy treatment followed by surgical resection the next day.

Who may qualify: Active tumor required; Thyroid tumor; Planned surgery

May not qualify if: Unresectable tumor; Anesthesia contraindicated; Other life threatening disease

Costs / coverage: 🟡 Partially funded — the study covers the pre-planning MRI and one histotripsy treatment and provides a $3,000 credit toward thyroid-tumor resection at Virginia Tech; standard surgical workup and remaining care are not stated as covered.

Contact: Robyn Fox, LVT, Clinical Trials Coordinator — robynfox@vt.edu

Official study / enrollment information →

Compassionate-Use Protocol for Advanced Non-Resectable Tumors

UT Southwestern Veterinary Research and Oncology Clinic · USA

Location

Veterinary Research and Oncology Clinic, 5801 Forest Park Rd, Dallas, TX 75235

Study details

Current

What is being offered: Investigational therapy, chemotherapy, immunotherapy and combination approaches under a prospective compassionate-use protocol

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Min weight kg exclusive: 2.5; min expected survival weeks: 3 weeks; Adequate organ function

May not qualify if: Severe systemic disease

Costs / coverage: ⚪ Owner-paid. The protocol brochure states that owners fully pay for the study, although possible subsidies may be available.

Contact: Paige Neumann, Research Study Coordinator — 214-645-6221; VROC@UTSouthwestern.edu

Official study / enrollment information →

Single-fraction SABR for progressive canine lung metastases

Tufts Cummings School of Veterinary Medicine · USA

Location

Henry and Lois Foster Hospital for Small Animals, 200 Westboro Rd, North Grafton, MA 01536

Study details

Recruiting

What is being offered: Single highly focused radiation dose for dogs with 2–10 progressive pulmonary metastatic nodules. The primary tumor, regional nodes and any non-pulmonary metastases must already be controlled; progression must be documented over 6–8 weeks, and all progressive lung lesions at least 5 mm must be safely treatable. Prior systemic therapy is allowed; cytotoxic chemotherapy pauses around SABR, while tolerated targeted therapy or immunotherapy may continue with radiation-oncologist approval. Tufts prescreening is required.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Metastatic; Measurable lung metastases; Planned radiation

Costs / coverage: 🟡 Partially funded. The study covers SABR, the one-month follow-up, adverse-event rechecks related to lung toxicity, and up to $860 toward the 2–3-month CT visit. Owners pay pre-enrollment bloodwork, chest imaging, treatment-planning CT, and diagnostic confirmation.

Contact: Tufts Clinical Trials Office — clinicaltrials@tufts.edu; owner and referring-veterinarian prescreening questionnaires on the official page

Official study / enrollment information →